Revolutionizing upstream gene therapy manufacturing with nanofiber microcarriers

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Are you looking for new cell culture systems to improve your AAV upstream bioprocessing? Improved cell culture product yield, faster processes, and scale-up can all result in an enhanced process economy in upstream gene therapy manufacturing.

Join us for an exclusive launch webinar of the world’s first nanofiber-based microcarriers designed to boost viral vector titers and improve productivity to much higher levels than current processes in gene therapy manufacturing. We will present data from scaling up AAV processes from cell culture flasks to stirred tank bioreactors.

Don't miss the chance to listen to Associate Professor in Medical Innovation, John Counsell, PhD, UCL, presenting exciting benchmarking results from the use of Cellevat3d® nanofiber-based microcarriers in AAV9 production compared to current standard microcarriers.

Attend this webinar to learn:

• How to enhance product titers in upstream bioprocessing with nanofiber microcarriers, with up to 60x larger surface area-to-volume ratio than current microcarriers, to support higher cell densities and enhancing viral vector production titers
• How to provide optimal conditions for cell growth through the formation of homogeneous spheroids to generate high viable cell densities (VCD) in stirred tank bioreactors
• How the nanofiber cell culture systems can be functionalized and easily molded into any shape, allowing for integration in various production platforms for gene therapy, cell therapy, and novel vaccines
• How to increase productivity and improve process economy

John Counsell

Associate Professor in Medical Innovation at UCL Research Department of Targeted Intervention

Dr John Counsell is an Associate Professor in the UCL Research Department of Targeted Intervention. His research group develop novel gene therapy technologies that seek to mitigate safety and durability issues associated with existing technologies. He is actively involved in translation and commercialisation of gene therapies across UCL, whilst providing contract research services for companies looking to validate their technologies for gene and cell therapy applications.

Laura Chirica

CEO at Cellevate AB

Laura Chirica has 20+ years of experience from executive roles in company strategy, commercialization, scaleup, growth and financing in both startups and multinationals from bioprocess, biotech and diagnostics industries. Her previous positions include Chief Commercial Officer at Immunovia AB, VP Sales and Marketing at Euro Diagnostica AB including Wieslab Service Laboratories (now SVAR Life Science), Director Purification Technologies Europe at Sartorius Stedim, Global Marketing Director at Dako A/S (now Agilent Technologies), and Global Marketing Program Manager at GE Healthcare (now Cytiva).

Linda Mellby

Vice President, R&D at Cellevate AB

Linda has more than 10 years of experience from leading research and development organization in the diagnostic industry. Linda brings extensive experience in building and leading the organization through startup process into commercialization phase, driving development programs from early research phases through optimization and validation to product launch and sales. Her previous position includes Vice President Research and Development at Immunovia AB.

in 7

Days

Register

SPEAKERS

John Counsell

Associate Professor in Medical Innovation at UCL Research Department of Targeted Intervention

Laura Chirica

CEO at Cellevate AB

Linda Mellby

Vice President, R&D at Cellevate AB

You might also like

Revolutionizing cell and gene therapy with digitalization: a panel discussion with industry leaders

C Harrison, R Street-Howards, K Deshpande

8 October

Watch

Streamlining immune cell therapy manufacturing workflows with single-use cytokines

Gabriella Perell

19 June

Watch

Case study: becoming the first GMP-certified cell and gene therapy manufacturing facility in Thailand

Kitipong Uaesoontrachoon

28 November 2023

Watch

Can primary packaging selection help mitigate particulate risks in cell and gene therapy manufacturing?

S Werner, S Curbishley, J Jendusa

10 April

Watch